Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 94

Sort by

Sort Order Select

Journal Articles

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

John M. Burke, Jeff Sharman, Bertrand Anz, Richard Zuniga, Aung Tun, David Wright, Prachi Jani, Juliana Biondo, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Jose Villasboas Bisneto, Elizabeth Budde, Ian Flinn

Blood (2025) 146 (Supplement 1): 228.

https://doi.org/10.1182/blood-2025-228

Published: 2025

Journal Articles

Real-world (RW) treatment (Tx) patterns, factors associated with discontinuation and toxicity across covalent BTK inhibitors (cBTKis) in first-line (1L) tx of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

John M. Burke, Enrico De Nigris, Yunfei Wang, Kathleen Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Diana Chirovsky, Siyang Leng, Ira Zackon

Blood (2025) 146 (Supplement 1): 2111.

https://doi.org/10.1182/blood-2025-2111

Published: 2025

Journal Articles

Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitors (cBTKis) or B-cell lymphoma 2 inhibitors (BCL2is)

John M. Burke, Enrico De Nigris, Yunfei Wang, Kathleen Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Diana Chirovsky, Inkyu Kim, Siyang Leng, Ira Zackon

Blood (2025) 146 (Supplement 1): 3888.

https://doi.org/10.1182/blood-2025-3888

Published: 2025

Journal Articles

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Jose Villasboas Bisneto, John M. Burke, Aung Tun, Steve Liu, Jeff Sharman, Juliana Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Javier Munoz, Furhan Yunus, Ian Flinn, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2025-1807

Published: 2025

Journal Articles

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

Jeff Sharman, Aung Tun, Jose Villasboas Bisneto, Ayed Ayed, Prachi Jani, Juliana Biondo, Mei Wu, Farah Hossain, Yong Mun, Vivek S. Chopra, Rona Farighi, Jamal Misleh, Shachar Peles, Ian Flinn, John M. Burke

Blood (2025) 146 (Supplement 1): 62.

https://doi.org/10.1182/blood-2025-62

Published: 2025

Journal Articles

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Blood (2025) 146 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2025-3730

Published: 2025

Journal Articles

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

Mazyar Shadman, Ian Flinn, Moshe Levy, Steven Papish, John M. Burke, Jamal Misleh, Jennifer Cultrera, Habte Yimer, Edwin Kingsley, Charles Farber, James D'Olimpio, Nan Sun, Adam Idoine, Jeff Sharman

Blood (2025) 146 (Supplement 1): 5663.

https://doi.org/10.1182/blood-2025-5663

Published: 2025

Journal Articles

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

Blood (2025) 145 (3): 290–299.

https://doi.org/10.1182/blood.2024024681

Published: 2025

Includes: Supplemental data

Journal Articles

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Matthew S. Davids, John M. Burke, Jennifer A. Woyach, Mina Shahkarami, Katherine Eakle, Jinnie Ko, Vivek S. Chopra, Weize Huang, Rona Farighi, Richard H. Ko, Jeff P. Sharman, William G. Wierda

Blood (2024) 144 (Supplement 1): 3257.2.

https://doi.org/10.1182/blood-2024-201555

Published: 2024

Journal Articles

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Blood (2024) 144 (Supplement 1): 658.

https://doi.org/10.1182/blood-2024-200925

Published: 2024

Journal Articles

Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey

Ryan Jacobs, Luke Fletcher, Andrew Rettew, Sophia S Li, Katherine Eakle, Mina Shahkarami, Rongrong Wang, Tu My To, Susan D Mathias, Isabella Manigault, John M. Burke

Blood (2024) 144 (Supplement 1): 2268.

https://doi.org/10.1182/blood-2024-198466

Published: 2024

Journal Articles

Clinical Outcomes and Adverse Events Among Patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Initiating First-Line (1L) Ibrutinib: Analysis of Subgroups Receiving Subsequent Second Generation (2G) Bruton Tyrosine Kinase Inhibitors, Non-Bruton Tyrosine Kinase Inhibitor Therapy, or Ibrutinib Retreatment in the US Community Oncology Setting

John M. Burke, Ira Zackon, Brittani Wayne, Yunfei Wang, John Murphy, Jennifer Prescott, Shravanthi Gandra, Siyang Leng, Enrico De Nigris

Blood (2024) 144 (Supplement 1): 7811.

https://doi.org/10.1182/blood-2024-203667

Published: 2024

Journal Articles

Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

John M. Burke, Ziqi Zhou, Cynthia Gutierrez, Anran Shao, Marley Boyd, Sina Noshad, Andriana Hohlbauch, Nicholas Liu, Karen Repetny, Michelle Fanale, Betsy Mitchell, Tycel Phillips

Blood (2024) 144 (Supplement 1): 7810.

https://doi.org/10.1182/blood-2024-203554

Published: 2024

Journal Articles

A Retrospective Analysis of US Commercial and Medicare Closed-Claims Databases to Evaluate Real-World Characteristics and Treatment Patterns of Patients with Diffuse Large B-Cell Lymphoma (2017-2023)

Tycel Phillips, Ziqi Zhou, Cynthia Gutierrez, Anran Shao, Marley Boyd, Sina Noshad, Andriana Hohlbauch, Nicholas Liu, Karen Repetny, Michelle Fanale, Betsy Mitchell, John M. Burke

Blood (2024) 144 (Supplement 1): 7809.

https://doi.org/10.1182/blood-2024-203380

Published: 2024

Journal Articles

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Benjamin B. Freeman, Ben Zhang, John M. Burke, Jennifer L. Cultrera, Habte A. Yimer, Edwin C. Kingsley, Charles M. Farber, James D'Olimpio, Hui Yao, Adam Idoine, Qi An, Jeff P. Sharman

Blood (2024) 144 (Supplement 1): 4632.

https://doi.org/10.1182/blood-2024-198250

Published: 2024

Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2024) 144 (Supplement 1): 886.

https://doi.org/10.1182/blood-2024-198147

Published: 2024

Journal Articles

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Blood (2024) 144 (Supplement 1): 3132.1.

https://doi.org/10.1182/blood-2024-194909

Published: 2024

Journal Articles

Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

John M. Burke, Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, Steven Liu, Juliana M.L. Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Jessica M. Grindheim, Dana Farinella, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 3008.

https://doi.org/10.1182/blood-2024-194604

Published: 2024

Journal Articles

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 460.

https://doi.org/10.1182/blood-2024-200992

Published: 2024

Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Blood (2024) 144 (Supplement 1): 469.

https://doi.org/10.1182/blood-2024-197938

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

Real-world (RW) treatment (Tx) patterns, factors associated with discontinuation and toxicity across covalent BTK inhibitors (cBTKis) in first-line (1L) tx of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey

Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

A Retrospective Analysis of US Commercial and Medicare Closed-Claims Databases to Evaluate Real-World Characteristics and Treatment Patterns of Patients with Diffuse Large B-Cell Lymphoma (2017-2023)

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only